Amyotrophic Lateral Sclerosis (ALS) Pipeline Projects Vast Growth Ahead

  • Published: May 2017

According to a new research report “Amyotrophic Lateral Sclerosis Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, Amyotrophic lateral sclerosis currently exhibits a pipeline with 72 drug candidates.

Browse Report Description at:

Amyotrophic Lateral Sclerosis pipeline offers novel therapeutic targets for the treatment of Amyotrophic lateral sclerosis

The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 72 drug candidates in different stages of development.

Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region. The progressive degeneration of neurons from brain to the spinal cord and spinal cord to the whole body can ultimately lead to their death. Amyotrophic lateral sclerosis is classified into two types, namely, sporadic and familial. Approximately 90% to 95% of the patients suffering from the disease in the U.S. are experience the sporadic.

Insights on pipeline segments

According to the route of administration analysis, most of the drug candidates are being developed to be administered by oral route.

NurOwn technology platform for Amyotrophic Lateral Sclerosis drug development

NurOwn is a cell therapy platform that builds on the enormous research effort that has gone into developing mesenchymal stem cells (MSCs) as a treatment for human diseases.

Major companies collaborate for the development of Amyotrophic Lateral Sclerosis Pipeline

The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan.

Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, and others.

Amyotrophic Lateral Sclerosis Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Molecule Type
  • By Company